Ethinamate

Ethinamate is a short-acting carbamate sedative-hypnotic medication used primarily in the treatment of insomnia. Despite its effectiveness in inducing sleep, its use has been limited due to the potential for abuse and dependence, as well as the availability of safer alternatives. Ethinamate acts on the central nervous system (CNS) to produce its sedative effects, although the exact mechanism of action is not fully understood. It is believed to modulate the action of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits neural activity, thereby promoting sleep.

Medical Uses

Ethinamate is indicated for the short-term treatment of insomnia. It helps decrease the time to fall asleep and increases the duration of sleep. However, due to its side effects and potential for dependence, it is usually not the first choice for treating insomnia.

Pharmacology

The pharmacological action of ethinamate is primarily through the enhancement of GABAergic transmission in the brain. By facilitating the action of GABA, ethinamate increases the inhibition of the CNS, leading to sedative and hypnotic effects. This mechanism is similar to that of other sedative-hypnotic drugs, such as barbiturates and benzodiazepines.

Side Effects

The use of ethinamate can lead to several side effects, including drowsiness, dizziness, confusion, and ataxia. More severe side effects may include respiratory depression, especially when combined with other CNS depressants, and the development of tolerance and dependence with prolonged use.

Contraindications

Ethinamate is contraindicated in individuals with a history of hypersensitivity to the drug, those with severe respiratory insufficiency, and patients with a history of substance abuse. It should be used with caution in individuals with liver impairment or those taking other medications that depress the CNS.

Interactions

Ethinamate can interact with other CNS depressants, such as alcohol, opioids, and benzodiazepines, leading to enhanced sedative effects and increased risk of respiratory depression. It may also interact with certain medications metabolized by the liver, altering their effects.

Withdrawal

Abrupt discontinuation of ethinamate after prolonged use can lead to withdrawal symptoms, including anxiety, agitation, tremors, and insomnia. Gradual dose reduction is recommended to minimize withdrawal effects.

Legal Status

The legal status of ethinamate varies by country, but it has been withdrawn from the market in many regions due to its side effects and potential for abuse. In some countries, it is classified as a controlled substance.

See Also

• Sedative-hypnotics
• Insomnia
• GABAergic drugs
• Substance dependence

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian